ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Celgene has struck another long-term drug discovery deal with Evotec, a contract research firm in Hamburg, Germany. For an up-front payment of $65 million, Evotec will apply its phenotypic screening platform and compound libraries to discovering drugs for solid tumors. No details about milestone payments were disclosed. Celgene says it is pleased with a partnership it formed with Evotec in December 2016 in which it paid $45 million for neurodegenerative disease drug discovery.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X